|
It was reported that the patient received inappropriate anti-tachycardia pacing (atp) and high voltage therapy after the device feature, designed to withhold ventricular tachyarrhythmia detection when there is sensed 1:1 atrial to ventricular conduction of rhythms that exhibit a gradual increase in rate into the detection zone, detected supra ventricular tachycardia (svt) as fast ventricular tachycardia (fvt).The cardiac resynchronization therapy defibrillator (crt-d) remains in use.No further patient complications have been reported as a result of this event.
|
|
Continuation of d10: 694758 lead implanted (b)(6) 2008, 5076-45 lead implanted (b)(6) 2012, 429688 lead implanted (b)(6) 2013.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|